Hema Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 7.00 M
as on 16-11-2024
- Paid Up Capital ₹ 6.98 M
as on 16-11-2024
- Company Age 36 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 10.67 Cr
as on 16-11-2024
- Satisfied Charges ₹ 4.64 Cr
as on 16-11-2024
- Revenue 1.59%
(FY 2023)
- Profit 18.56%
(FY 2023)
- Ebitda 1.03%
(FY 2023)
- Net Worth 15.02%
(FY 2023)
- Total Assets -6.24%
(FY 2023)
About Hema Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 7.00 M and a paid-up capital of Rs 6.98 M.
The company currently has active open charges totaling ₹10.67 Cr. The company has closed loans amounting to ₹4.64 Cr, as per Ministry of Corporate Affairs (MCA) records.
Jigneshkumar Chodvadiya and Manishbhai Thumar serve as directors at the Company.
- CIN/LLPIN
U24230GJ1988PTC010557
- Company No.
010557
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Apr 1988
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Vadodara, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Hema Pharmaceuticals Pvt Ltd offer?
Hema Pharmaceuticals Pvt Ltd offers a wide range of products and services, including Pharma Ingredients & Raw Materials, Antipyretic and Analgesic API, Chemical Intermediates, 2 Iodobenzoic Acid, Cardiovascular Drugs & Medication, Cholesterol Medicine, API Intermediate, 5-Bromo-2-chlorobenzoic Acid, Antihistamines, Levocetirizine Tablet.
Who are the key members and board of directors at Hema Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jigneshkumar Chodvadiya  | Director | 31-Jul-2015 | Current |
| Manishbhai Thumar | Director | 22-Oct-2012 | Current |
Financial Performance of Hema Pharmaceuticals.
Hema Pharmaceuticals Pvt Ltd, for the financial year ended 2023, experienced modest growth in revenue, with a 1.59% increase. The company also saw a substantial improvement in profitability, with a 18.56% increase in profit. The company's net worth Soared by an impressive increase of 15.02%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Hema Pharmaceuticals?
In 2023, Hema Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 29 Jun 2016 | ₹10.67 Cr | Open |
Bank Of Baroda Creation Date: 12 Mar 2013 | ₹4.37 Cr | Satisfied |
Gujarat Staste Financial Corporation Creation Date: 21 Oct 1989 | ₹2.68 M | Satisfied |
How Many Employees Work at Hema Pharmaceuticals?
Hema Pharmaceuticals has a workforce of 63 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hema Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hema Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
